No results for ‘’
Gennex Laboratories Ltd
₹11.10
(0.98%)
Sat, 19 Sept 2026, 10:40 pm
Health Technology
Pharmaceuticals: Major
24.5KGennex Laboratories Price to Cash Flow Ratio
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 14.85 | 70.63 | 64.69 | 0 | 50.04 | 36.36 | 37.69 | 57.99 | 34.43 | 47.94 | 22.43 | 56.33 | 17.71 | 12.67 | 12.25 | 24.28 | 16.65 | 22.40 | 15.12 |
| Price to book ratio | 0.51 | 0.67 | 2.20 | 0.76 | 0.91 | 0.78 | 0.56 | 0.57 | 0.47 | 0.89 | 4 | 1.98 | 1.49 | 1.17 | 0.66 | 1.25 | 2.18 | 1.24 | 2.11 | 1.47 |
| Price to sales ratio | 1.17 | 0.96 | 2.44 | 1.28 | 1.46 | 0.99 | 0.56 | 0.48 | 0.34 | 0.71 | 2.91 | 1.45 | 1.08 | 0.71 | 0.42 | 0.83 | 1.56 | 1.25 | 3.40 | 1.99 |
| Price to cash flow ratio | 0 | 76.72 | 0 | 0 | 2.88 | 10.18 | 6.27 | 0 | 53.38 | 0 | 38.72 | 0 | 18.73 | 34.85 | 0 | 0 | 19.61 | 3.28 | 0 | 0 |
| Enterprise value | 8.83Cr | 11.85Cr | 54.26Cr | 20.29Cr | 23.5Cr | 19.45Cr | 13.29Cr | 16.38Cr | 14.58Cr | 25.93Cr | 114Cr | 63.93Cr | 48.51Cr | 40.73Cr | 27.6Cr | 55.76Cr | 97.07Cr | 74.1Cr | 259Cr | 254Cr |
| Enterprise value to EBITDA ratio | 12.99 | 5.65 | 39.14 | 18.79 | 16.36 | 12.75 | 7.46 | 10.86 | 9.17 | 13.01 | 27.11 | 13.99 | 21.38 | 10.12 | 8.10 | 8.37 | 17.72 | 15.66 | 14.91 | 14.96 |
| Debt to equity ratio | 0.09 | 0.09 | 0.04 | 0.06 | 0.08 | 0.06 | 0.08 | 0.10 | 0.13 | 0.15 | 0.09 | 0.12 | 0.08 | 0.14 | 0.14 | 0.19 | 0.23 | 0.01 | 0.11 | 0.15 |
| Return on equity % | 0 | 4.62 | 3.77 | 1.22 | -2.87 | 1.68 | 1.53 | 1.60 | 0.82 | 2.59 | 8.76 | 9.20 | 2.68 | 6.81 | 5.37 | 10.77 | 9.44 | 7.95 | 10.53 | 10.16 |
Gennex Laboratories Ltd Price to Cash Flow Ratio
The Gennex Laboratories Ltd Price to Cash Flow Ratio is a key financial metric used by investors to evaluate Gennex Laboratories Ltd's valuation, profitability, and overall financial performance. Tracking the Gennex Laboratories Ltd Price to Cash Flow Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Gennex Laboratories Ltd (NSE: , BSE: 531739) is currently trading at ₹11.10, with a market capitalization of ₹251.1Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Gennex Laboratories Ltd Price to Cash Flow Ratio is essential for fundamental analysis.
Gennex Laboratories Ltd Price to Cash Flow Ratio Current Value
The current Gennex Laboratories Ltd Price to Cash Flow Ratio stands at 0.
The Gennex Laboratories Ltd Price to Cash Flow Ratio remains stable, indicating consistent financial performance.
Gennex Laboratories Ltd Price to Cash Flow Ratio Historical Trend
The Gennex Laboratories Ltd Price to Cash Flow Ratio has shown the following historical trend:
- 2024: 0
- 2023: 0
- 2022: 3.28
- 2021: 19.61
- 2020: 0
The decline in Gennex Laboratories Ltd Price to Cash Flow Ratio indicates improving financial efficiency or better earnings growth.
What Gennex Laboratories Ltd Price to Cash Flow Ratio Indicates for Investors
The Gennex Laboratories Ltd Price to Cash Flow Ratio plays a crucial role in understanding the company's financial health and valuation.
The P/CF ratio indicates how much investors pay for company cash flow.
Gennex Laboratories Ltd Price to Cash Flow Ratio Analysis Summary
The Gennex Laboratories Ltd Price to Cash Flow Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Gennex Laboratories Ltd Price to Cash Flow Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Gennex Laboratories Ltd Price to Cash Flow Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.